Yong Ben - 11 Aug 2025 Form 3 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Role
Chief Med & Dev Officer
Signature
/s/ Aaron Chan, Attorney-in-Fact
Issuer symbol
HLXB
Transactions as of
11 Aug 2025
Net transactions value
$0
Form type
3
Filing time
18 Aug 2025, 17:11:30 UTC
Previous filing
02 Jun 2025
Next filing
28 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ben Yong Chief Med & Dev Officer BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO /s/ Aaron Chan, Attorney-in-Fact 18 Aug 2025 0001967669

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBOT Stock Option (Right to Buy) 11 Aug 2025 Common Stock 443,298 $4.17 Direct F1
holding BBOT Stock Option (Right to Buy) 11 Aug 2025 Common Stock 26,551 $7.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying such option shall vest on September 3, 2025, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date.
F2 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney